Although CGRP may have contrasting effects in broncho-pulmonary physiology [5], it could amplify bronchoconstriction [184] and surveillance only is recommended in patients treated with anti-CGRP/rec mAbs since no deleterious signals in obstructive pulmonary disease or in pulmonary hypertension have yet appeared in pharmacovigilance databases. This evidence concerns the gene CALCA and pulmonary hypertension.